ethosuximide, phenobarbital, carbamazepine, primidone, valproic acid). ⢠Newer AEDs were defined as AEDs that became available from 1993 onwards (e.g., ...
Antiepileptic drug utilization across 15 years for epilepsy and non-epilepsy indications in a Canadian province: A population-based study Christine Leong, PharmD1; Muhammad M. Mamdani, MPH, MA, PharmD2; Tara Gomes, BScH, MHSc2 ; David N. Juurlink, BPhm, MD, FRCP, PhD1; Erin M. Macdonald, MSc3; Marina Yogendran, MSc3 College of Pharmacy, Apotex Centre, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada; 2 Institute for Clinical Evaluative Science, Toronto, Ontario, Canada; 3 Manitoba Centre for Health Policy; College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada. *Conflict of Interest Statement: Dr. Mamdani has served as an Advisory Board member for the following pharmaceutical companies: Astra Zeneca, Bristol-Myers Squibb, Eli Lilly and Company, Glaxo Smith Kline, Hoffman La Roche, Novartis, Novo Nordisk, Pfizer. All other authors have no conflicts of interest to disclose.
1
Background
Results
• Recent evidence suggests a growing use of antiepileptic drugs (AED) for the management of non-epileptic conditions such as pain, mood, and anxiety.
Figure 1 – Crude prevalence rates of AED users with epilepsy 700
• Newer AEDs may impart a better tolerability profile, reduced drug interaction potential, and reduced need for therapeutic drug monitoring compared to traditional AEDs.
600 Newer AED with Epilepsy Users per 1000
• Prescribing trends can be used to examine the uptake of guideline recommendations and treatment preferences over time.
Older AED with Epilepsy
650 to 446 per 1000; p
